Create Free Account

By creating account you will get access to hot stocks & personalised emails

Anatara Lifesciences Ltd

Healthcare AU ANR

0.043AUD
0.007(19.44%)

Last update at 2024-05-09T05:50:00Z

Day Range

0.040.04
LowHigh

52 Week Range

0.020.05
LowHigh

Financials

Income Statement

Balancesheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Type yearly yearly yearly yearly yearly
Date 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Income before tax -2.02319M -2.53229M -1.99587M -3.36464M -2.86827M
Minority interest - - - - -
Net income -2.02319M -2.53561M -3.10420M -3.31258M -1.84820M
Selling general administrative 0.89M 1.38M 1.62M 2.06M 2.51M
Selling and marketing expenses - - - - -
Gross profit - - - - 0.66M
Reconciled depreciation 0.02M 0.02M 0.00626M 0.02M 0.02M
Ebit -2.02082M -2.52897M -1.99557M -4.20592M -3.88835M
Ebitda -1.99605M -2.50430M -1.98931M -4.18982M -3.86562M
Depreciation and amortization 0.02M 0.02M 0.00626M 0.02M 0.02M
Non operating income net other - - - - -
Operating income -2.02082M -2.52897M -1.99557M -4.20592M -3.88835M
Other operating expenses 3.28M 3.02M 3.11M 4.21M 4.55M
Interest expense 0.00237M 0.00332M 0.00030M 0.00000M 0.00000M
Tax provision 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Interest income 0.02M 0.00600M 0.00912M 0.05M 0.14M
Net interest income 0.02M 0.00268M 0.00882M 0.05M 0.14M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 1.25M 0.00332M 1.11M -0.05206M -1.02007M
Total revenue - 0.00000M 0.00000M 0.00000M 0.66M
Total operating expenses 3.28M 3.02M 3.11M 4.21M 4.55M
Cost of revenue - - - - 0.78M
Total other income expense net 1.25M -0.00332M -0.00030M 0.84M 1.02M
Discontinued operations - - - - -
Net income from continuing ops -2.02319M -2.53229M -1.99587M -3.36464M -2.86827M
Net income applicable to common shares -2.02319M -2.53229M -1.99587M -3.36464M -2.86827M
Preferred stock and other adjustments - - - - -
Breakdown 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Type yearly yearly yearly yearly yearly
Date 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Total assets 1.42M 1.77M 4.33M 3.34M 6.38M
Intangible assets - - - 0.00000M 0.00705M
Earning assets - - - - -
Other current assets 0.01M 0.02M 0.04M 0.02M 0.05M
Total liab 0.49M 0.40M 0.50M 0.49M 0.47M
Total stockholder equity 0.92M 1.36M 3.83M 2.86M 5.92M
Deferred long term liab - - - - -
Other current liab 0.42M 0.21M 0.21M 0.43M 0.34M
Common stock 21.37M 19.91M 19.76M 17.04M 16.94M
Capital stock 21.37M 19.91M 19.76M 17.04M 16.94M
Retained earnings -20.79188M -18.98366M -16.60401M -14.73627M -11.52490M
Other liab 0.00067M 0.00008M 0.03M 0.02M 0.01M
Good will - - - - -
Other assets - - - - -
Cash 0.35M 1.12M 3.43M 2.68M 1.36M
Cash and equivalents - - - - -
Total current liabilities 0.49M 0.36M 0.40M 0.46M 0.45M
Current deferred revenue - -0.02066M -0.01412M -0.01412M -
Net debt -0.35118M -1.05440M -3.35216M -2.68237M -1.36008M
Short term debt 0.00000M 0.02M 0.01M 0.01M 4.05M
Short long term debt - - - - -
Short long term debt total - 0.07M 0.08M 0.08M -
Other stockholder equity -0.57684M -0.92482M -3.15163M -2.30332M 0.50M
Property plant equipment 0.00326M 0.07M 0.09M 0.00719M 0.02M
Total current assets 1.42M 1.70M 4.24M 3.34M 6.36M
Long term investments - - - - -
Net tangible assets 0.92M 1.36M 3.83M 2.86M 5.91M
Short term investments 0.05M 0.05M 0.05M 0.00000M 4.05M
Net receivables 1.00M 0.51M 0.77M 0.63M 0.90M
Long term debt - - - - -
Inventory - - - - -
Accounts payable 0.08M 0.15M 0.20M 0.03M 0.12M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 0.35M 0.44M 0.68M 0.55M 0.50M
Additional paid in capital - - - - -
Common stock total equity - - - 17.04M 16.94M
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other -0.00326M -0.06692M -0.08503M -0.00719M 0.03M
Deferred long term asset charges - - - - -
Non current assets total 0.00326M 0.07M 0.09M 0.00719M 0.03M
Capital lease obligations - 0.07M 0.08M - -
Long term debt total 0.00000M 0.05M 0.07M 0.00000M 0.00000M
Breakdown 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Type yearly yearly yearly yearly yearly
Date 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Investments -0.00173M -0.05000M -0.00398M 4.05M 2.15M
Change to liabilities 0.17M -0.03351M -0.07691M 0.05M -0.05496M
Total cashflows from investing activities -0.00173M -0.05656M -0.00398M 4.05M 2.15M
Net borrowings -0.01819M -0.01744M -0.00051M -0.00051M -0.00051M
Total cash from financing activities 1.49M -0.02244M 2.85M 2.85M 2.85M
Change to operating activities -0.00793M -0.03057M -0.00668M 0.00473M -0.67780M
Net income -2.02319M -2.53229M -1.99587M -3.36464M -1.84820M
Change in cash -0.76902M -2.31187M 0.75M 1.32M -0.08765M
Begin period cash flow 1.12M 3.43M 2.68M 1.36M 1.45M
End period cash flow 0.35M 1.12M 3.43M 2.68M 1.36M
Total cash from operating activities -2.25790M -2.23288M -2.09748M -2.72490M -2.23766M
Issuance of capital stock 1.70M - 3.03M - -
Depreciation 0.02M 0.02M 0.00626M 0.02M 0.02M
Other cashflows from investing activities 0.00000M -0.05000M 0.00000M 4.05M 2.15M
Dividends paid - - - - -
Change to inventory - - - - -
Change to account receivables -0.49555M 0.26M -0.14223M 0.27M 1.14M
Sale purchase of stock -0.18868M -0.00500M -0.18069M -0.18069M -
Other cashflows from financing activities -0.01819M -0.01744M -0.00051M 4.05M 2.34M
Change to netincome 0.07M 0.07M 0.12M 0.31M 0.20M
Capital expenditures 0.00173M 0.00656M 0.00398M 0.00408M 0.00408M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital -0.49555M 0.26M -0.14223M 0.27M 1.49M
Stock based compensation 0.05M 0.07M 0.12M 0.31M -
Other non cash items -0.25947M 0.27M -0.10787M 0.62M 2.85M
Free cash flow -2.25962M -2.23944M -2.10146M -2.72898M -0.00408M

Fundamentals

  • Previous Close 0.04
  • Market Cap8.23M
  • Volume93453
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-1.75754M
  • Revenue TTM-0.12318M
  • Revenue Per Share TTM-0.001
  • Gross Profit TTM -1.60223M
  • Diluted EPS TTM-0.01

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (AUD) Price (AUD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
ANR
Anatara Lifesciences Ltd		 0.007 19.44% 0.04 - - 4.04 5.43 5.29 -2.7845
CSL
CSL Ltd		 -2.85 1.02% 277.05 35.44 31.35 9.60 5.16 10.91 34.93
TLX
Telix Pharmaceuticals Ltd		 0.07 0.46% 15.35 748.00 21.01 8.47 28.69 8.21 177.65
NEU
Neuren Pharmaceuticals Ltd		 -0.79 3.93% 19.31 15.98 38.46 11.63 13.15 10.65 12.39
MSB
Mesoblast Ltd		 -0.04 3.54% 1.09 - 769.23 116.88 1.12 126.11 -19.3368

Reports Covered

Stock Research & News

View All

Profile

Anatara Lifesciences Ltd engages in the research, development, and commercialization of evidence-based solutions for gastrointestinal diseases in animals and humans in Australia. It offers Gastrointestinal ReProgramming, a proprietary formulation that combines bromelain with other evidence-based ingredients to address the primary underlying factors associated with human gastrointestinal conditions, such as irritable bowel syndrome and inflammatory bowel disease. The company also provides Detach for the treatment of diarrhea disease in piglets; BONIFF, a revised formulation to dry feed for piglets after weaning; and ANR-pf, a proprietary formulation for poultry in water. Anatara Lifesciences Ltd was incorporated in 2010 and is based in Adelaide, Australia.

Anatara Lifesciences Ltd

81 Flinders Street, Adelaide, SA, Australia, 5000

Key Executives

Name Title Year Born
Dr. David Lionel Brookes FACRRM, FAICD, MBBS Exec. Chairman 1960
Mr. John Michailidis B.Sc., EMBA, M.A.I.C.D. Chief Operations Officer NA
Jane Lowe Managing Director of IR Department NA
Mr. Simon Erskine Chief Devel. Officer NA
Dr. Stephen Denaro AGIA, BCom, CA, GradDipApp CG, MAICD Company Sec. NA
Ms. Hayley van der Meer B Biomed Sc, Grad Dip Marketing Management Commercial Mang. NA
Dr. David Lionel Brookes F.A.C.I.D., FACRRM, FAICD, MBBS Executive Chairman 1960
Mr. John Michailidis B.Sc., EMBA, M.A.I.C.D. COO & Executive Director NA
Mr. Simon Erskine Chief Development Officer NA
Dr. Stephen Denaro AGIA, BCom, CA, GradDipApp CG, MAICD Company Secretary NA

Disclaimer - Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peer trades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).

Our Company

Useful Links

Contact Us

Market Research

Our Company

Useful Links

Contact Us

Disclaimer

The information given by Kalkine Pty Ltd ABN34 154 808 312 (Australian Financial Services License Number 425376) on this website is general information or advice only.

It does not take into account any of your personal objectives, circumstances or needs. Choosing an investment is an important decision. If you do not feel confident making a decision based on the recommendations Kalkine has made in our reports, you should consider obtaining personal advice from an authorised adviser.

There may be a product disclosure statement or other offer document for the securities and financial products we write about in Kalkine Reports. You should obtain a copy of the product disclosure statement or offer document before making any decision about whether to acquire the security or product. Terms & Conditions have been provided for our services, please go through them and also read our Financial Services Guide.

Our website may contain information on past performance of particular investments. Past performance is not an indicator of future performance. Hypothetical returns may not reflect actual performance. Any displays of potential investment opportunities are for sample purposes only and may not actually be available to investors.

The information on the website does not constitute an offer to sell securities or a solicitation of an offer to buy securities. Our reports contain general recommendations to invest in securities.

Copyright 2024 Krish Capital Pty. Ltd. All rights reserved. No part of this website, or its content, may be reproduced in any form without our prior consent.